Cannabix Technologies to Participate at U.S. National Institute of Standards and Technology (NIST) Cannabis Breathalyzer Workshop
Cannabix Technologies (OTC:BLOZF), a developer of marijuana and alcohol breath testing devices, announced its participation in the inaugural cannabis breathalyzer workshop hosted by the U.S. National Institute of Standards and Technology (NIST). The workshop, titled "Building a Path Forward for Meaningful Cannabis Breathalyzer Realization," will be held at NIST's Colorado facilities in September.
The company will showcase its Marijuana Breath Test (MBT) technology, which detects recent cannabis use through delta-9-tetrahydrocannabinol (Δ9-THC) identification. The system features proprietary Breath Collection Unit (BCU) and Breath Cartridge (BC) technologies designed to collect and preserve breath samples for analysis using LC-MS methods.
Cannabix Technologies (OTC:BLOZF), sviluppatore di dispositivi per la rilevazione di droghe e alcol nel respiro, ha annunciato la sua partecipazione al primo workshop sul breathalyzer della cannabis organizzato dal National Institute of Standards and Technology (NIST) degli Stati Uniti. Il workshop, intitolato "Costruire un percorso verso una realizzazione significativa del breathalyzer per la cannabis", si terrà presso i stabilimenti del NIST in Colorado a settembre.
L'azienda presenterà la propria tecnologia Marijuana Breath Test (MBT), in grado di rilevare l'uso recente di cannabis tramite l'identificazione del delta-9-tetraidrocannabinolo (Δ9-THC). Il sistema integra tecnologie proprietarie di Breath Collection Unit (BCU) e Breath Cartridge (BC) pensate per raccogliere e conservare i campioni di respiro per l'analisi mediante metodi LC-MS.
Cannabix Technologies (OTC:BLOZF), desarrollador de dispositivos de prueba de aliento para marihuana y alcohol, anunció su participación en el taller inaugural de detectores de humo de cannabis organizado por la National Institute of Standards and Technology (NIST) de EE. UU.. El taller, titulado "Construyendo un camino hacia una realización significativa del detector de cannabis en aliento", se llevará a cabo en las instalaciones de Colorado del NIST en septiembre.
La empresa mostrará su tecnología Marijuana Breath Test (MBT), que detecta el uso reciente de cannabis mediante la identificación del delta-9-tetrahidrocannabinol (Δ9-THC). El sistema cuenta con tecnologías propietarias de Breath Collection Unit (BCU) y Breath Cartridge (BC) diseñadas para recoger y conservar muestras de aliento para su análisis mediante métodos LC-MS.
Cannabix Technologies (OTC:BLOZF)는 마리화나 및 알코올 호흡 측정 기기 개발사로서 미국 표준기술원(NIST) 주최의 첫 번째 대마초 호흡측정 워크숍에 참여할 것이라고 발표했다. 워크숍의 제목은 "의미 있는 대마초 호흡측정기의 실현을 향한 경로 구축"이며 9월에 NIST의 콜로라도 지부에서 개최될 예정이다.
회사는 최근 대마초 사용을 Δ9-THC 식별을 통해 감지하는 Marijuana Breath Test (MBT) 기술을 선보일 예정이다. 이 시스템은 분석을 위해 호흡 샘플을 수집·보존하도록 설계된 독점적인 Breath Collection Unit (BCU) 및 Breath Cartridge (BC) 기술을 특징으로 하며 LC-MS 방법으로 분석한다.
Cannabix Technologies (OTC:BLOZF), développeur d'appareils de détection d'alcool et de cannabis dans l'haleine, a annoncé sa participation au premier atelier sur les alcootests au cannabis organisé par le National Institute of Standards and Technology (NIST) des États-Unis. L'atelier, intitulé « Construire une voie vers une réalisation significative des tests d'haleine pour le cannabis », se déroulera dans les installations du NIST au Colorado en septembre.
L'entreprise présentera sa technologie Marijuana Breath Test (MBT), capable de détecter l'usage récent de cannabis grâce à l'identification du delta-9-tétrahydrocannabinol (Δ9-THC). Le système intègre des technologies propriétaires Breath Collection Unit (BCU) et Breath Cartridge (BC) conçues pour collecter et préserver les échantillons d'haleine pour analyse par méthodes LC-MS.
Cannabix Technologies (OTC:BLOZF), Entwickler von Messgeräten zur Atemanalyse von Marihuana und Alkohol, kündigte seine Teilnahme am ersten Cannabis-Atemschnelltest-Workshop an, der vom U.S. National Institute of Standards and Technology (NIST) ausgerichtet wird. Der Workshop mit dem Titel "Auf dem Weg zu einer sinnvollen Realisierung von Cannabis-Atemtests" findet im September in den Colorado-Anlagen des NIST statt.
Das Unternehmen wird seine Marijuana Breath Test (MBT) Technologie vorstellen, die den jüngsten Cannabiskonsum durch Identifikation von Δ9-THC nachweist. Das System verfügt über proprietäre Technologien der Breath Collection Unit (BCU) und der Breath Cartridge (BC), die entwickelt wurden, um Atemproben für Analysen mittels LC-MS zu sammeln und zu konservieren.
Cannabix Technologies (OTC:BLOZF)، مطور أجهزة فحص النفس للكحول والماريجوانا، أعلن عن مشاركته في ورشة العمل الافتتاحية لاختبار النفس للقنب التي تستضيفها المعهد الوطني للمعايير والتقنية الأمريكية (NIST). ستعقد الورشة المعنونة "بناء مسار للمضي قدمًا نحو تحقيق حقيقي لاختبار النفس للقنب" في مرافق NIST في كولورادو في سبتمبر.
ستعرض الشركة تقنيتها Marijuana Breath Test (MBT)، التي تكشف عن استخدام القنب مؤخراً من خلال تحديد Δ9-THC. النظام يشتمل على تقنيات حيازة التنفس Breath Collection Unit (BCU) و Breath Cartridge (BC) المصممة لجمع وحفظ عينات التنفس للتحليل باستخدام طرق LC-MS.
Cannabix Technologies (OTC:BLOZF)，是一家开发大麻与酒精呼气测试设备的公司，宣布参加由美国国家标准与技术研究院（NIST）主办的首届大麻呼气分析仪工作坊。此次工作坊题为“为大麻呼气分析仪实现铺平有意义之路”，将于九月在NIST位于科罗拉多的设施举行。
公司将展示其Marijuana Breath Test (MBT)技术，通过识别Δ9-四氢大麻酚（Δ9-THC）来检测最近的使用。该系统具备专有的Breath Collection Unit (BCU)与Breath Cartridge (BC)技术，旨在收集并保存呼气样本以供LC-MS方法分析。
- None.
- None.
VANCOUVER, British Columbia, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath testing devices reports that it will be attending the inaugural “Building a Path Forward for Meaningful Cannabis Breathalyzer Realization” workshop hosted by the United States National Institute of Standards and Technology (“NIST”).
NIST, a federal agency under the U.S. Department of Commerce, plays a key role in advancing measurement science, standards, and technology. This workshop will convene a select group of stakeholders from industry, government, forensic laboratories, academia, law enforcement, and standards organizations. The event will take place at NIST’s Colorado facilities in September.
The Company will be discussing its Cannabix Marijuana Breath Test (“MBT”) technology (Figure 1), which is designed to detect recent cannabis use by identifying the presence of delta-9-tetrahydrocannabinol (Δ9-THC) — the primary psychoactive compound in cannabis. The MBT system includes Cannabix’s proprietary Breath Collection Unit (BCU) and Breath Cartridge (BC) technologies, which are engineered to collect and preserve breath samples for analysis using gold-standard liquid chromatography-mass spectrometry (LC-MS) methods.
Figure 1. Sample Collection with Cannabix Breath Collection Unit
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana and alcohol breath technologies for workplaces, law enforcement and other settings. Breath testing for delta-9 THC (the primary psychoactive ingredient in cannabis) focuses on recent marijuana use. Cannabix is the developer of the BreathLogix autonomous alcohol screening device for organizations who strive to improve alcohol safety and monitoring
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEO
Cannabix Technologies Inc.
For further information, contact the Company at info@cannabixtechnologies.com
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plan," "continue," "expect," "project," "intend," "believe," "anticipate," "estimate," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements relating to: certification of devices, acceptance of devices by international regulators, the achievement of any or all of the goals and aims of the strategic partnership and development agreement with Omega Laboratories; the completion of pre-validation or validation testing described in this news release; final development of a commercial or prototype product(s); the successful trial or pilot of company technologies; the commercialization of the Company's products; the negotiation and potential entry into additional agreements with distributors; and the completion of future financings. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include (but are note limited to): adverse market conditions; risks regarding protection of proprietary technology; the ability of the Company to complete future financings; the ability of the Company to develop and market its future product; risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition; that Omega may not complete all or any of the milestones as contemplated strategic partnership and development agreement with Omega Laboratories; that the CSE may not approve the issuance of the securities; that the Company’s development of breathalyzer technology will provide any benefit to the Company; there is no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials; there is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies; there is no assurance that any “patent pending” or “provisional patents” technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities; the Company is not currently selling breathalyzers and there is no assurance that the Company ever will; and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7f9193ff-9f1a-425f-a180-b3bd0c414fdf
FAQ
What is the purpose of Cannabix Technologies' participation in the NIST workshop?
What technology will Cannabix (BLOZF) showcase at the NIST workshop?
When and where will the NIST cannabis breathalyzer workshop take place?
Who will attend the NIST cannabis breathalyzer workshop?
How does Cannabix Technologies' MBT system work?
